AIM ImmunoTech Inc. 8-K

What Happened

• AIM ImmunoTech, Inc. filed an 8-K on January 20, 2026 furnishing notices to holders that announce changes to the company’s Class E and Class F common stock purchase warrants. The notices were furnished as Exhibits 99.1 and 99.2 and are labeled as “furnished,” not “filed,” under the Securities Exchange Act (meaning they are not subject to Section 18 liability).

Key Details

• Filing date: January 20, 2026.
• Notices: Modifications to Class E and Class F common stock purchase warrants were sent to warrant holders (Exhibits 99.1 and 99.2).
• Legal note: The information is furnished (not filed) and can only be incorporated by reference in a later SEC filing if that later filing explicitly references it.
• Forward-looking disclaimer: The filing includes a cautionary statement about forward-looking statements and reiterates risks tied to development of the company’s drug candidate Ampligen® (need for more testing, clinical trial uncertainty, foreign-operational risks, and reference to the company’s Risk Factors in its Form 10-K/10-Q).

Why It Matters

• Warrant modifications can change the economic terms available to warrant holders and may affect potential dilution or future capital structure. The 8-K does not detail the new warrant terms in the body of the filing; investors should read the furnished notices (Exhibits 99.1 and 99.2) for the exact changes.
• The filing’s forward-looking statement reminder underscores that AIM’s clinical and commercial prospects for Ampligen® remain subject to significant regulatory, clinical and operational risks disclosed in its SEC filings.